Bisoprol tablets 10 mg blister No. 30

Biprolol tablets are indicated for:

Composition

Active ingredient: bisoprolol;

1 tablet contains bisoprolol fumarate in terms of 100% substance 5 mg or 10 mg;

Excipients: lactose monohydrate, microcrystalline cellulose, calcium hydrogen phosphate, crospovidone, colloidal anhydrous silica, sunset yellow FCF (E 110), magnesium stearate.

Contraindication

Method of application

Bisoprolol® tablets should be swallowed without chewing, in the morning on an empty stomach, during or after breakfast, with a small amount of liquid.

The maximum recommended dose of bisoprolol fumarate is 10 mg once daily.

Application features

Pregnant women

During pregnancy, the drug is used only when the expected benefit to the mother outweighs the potential risk to the fetus.

Children

Not applicable.

Drivers

With caution.

Overdose

Symptoms. In case of overdose (for example, a daily dose of 15 mg instead of 7.5 mg), cases of third-degree atrioventricular block, bradycardia and dizziness have been reported. Common signs of overdose with β-blockers are bradycardia, hypotension, acute heart failure, hypoglycemia and bronchospasm. Several cases of overdose in patients with arterial hypertension and/or ischemic heart disease (maximum dose - 2000 mg of bisoprolol) are currently known. Bradycardia and/or hypotension were noted. All patients recovered. There is a wide variability in individual sensitivity to a single high dose of bisoprolol; patients with heart failure may be more sensitive to the drug. Therefore, treatment should be started with a gradual increase in dosage.

Treatment. In case of overdose, discontinue treatment with the drug and provide supportive and symptomatic therapy. There are limited data, bisoprolol is difficult to dialyze. If overdose is suspected, the following general measures should be considered, in accordance with the expected pharmacological action and based on recommendations for other β-blockers.

Side effects

General disorders: Common: asthenia (in patients with chronic heart failure), fatigue*.
Uncommon: asthenia (in patients with arterial hypertension or ischemic heart disease).

* Applies only to patients with arterial hypertension or ischemic heart disease. These symptoms usually occur at the beginning of therapy, are mild and disappear within the first 1-2 weeks.

Interaction

Combinations not recommended for use. Treatment of chronic heart failure. Class I antiarrhythmics (e.g. quinidine, disopyramide, lidocaine, phenytoin, flecainide, propafenone): possible potentiation of the effect on AV conduction and increased negative inotropic effect.

Combinations to be used with caution. Treatment of arterial hypertension or ischemic heart disease (angina pectoris). Class I antiarrhythmics (e.g. quinidine, disopyramide, lidocaine, phenytoin, flecainide, propafenone): possible potentiation of the effect on AV conduction and increased negative inotropic effect.

Storage conditions

Store in the original packaging at a temperature not exceeding 25 °C.

Keep out of reach of children.

Shelf life - 3 years.